CAB-AXL-ADC Safety and Efficacy Study in Adults With NSCLC
← catalyst calendarSponsored by BioAtla, Inc. (industry) · BCAB — their whole pipeline →.
Phase
Phase 2
Status
Completed
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
85actual
Sites
60
Countries
Greece, Hong Kong, Italy +4
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-03-17 | actual | When the study began enrolling |
| Primary completion | 2025-07-09 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-07-09 | actual | The whole study's end, after follow-up |
| First posted | 2020-12-23 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-09-25 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Non-Small-Cell Lung Cancer
Interventions
- Biological: CAB-AXL-ADC — also filed as BA3011
- Biological: PD-1 inhibitor
Primary outcomes
what the primary-completion date above is the date OFConfirmed Objective Response Rate (ORR) per RECIST v1.1
measured Up to 24 months
Incidence of Adverse Events (AEs)or Serious Adverse Events (SAEs) as assessed by CTCAE v4.03/v5
measured Up to 24 months
Permalink · BCAB's whole pipeline · Catalyst calendar · Every registered study · What changed